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retrieved from the G-BA homepage (https://www.g-ba.de/informationen/nutzenbe-
wertung/). Cut-off date for assessment inclusion was May 15th 2015. The following 
sources for extraction had to be available: Dossier module 3 (pharmaceutical com-
panies), G-BA decision/rationale (G-BA). Extraction included assessment date/type, 
active substance, indication(s), therapeutic area, target population in total/subgroups 
(min, max, exact) and data sources. Missing exact numbers were calculated from min/
max. For the analysis indications/subgroups clearly differing by written definition 
were excluded. Results: 147 indications were included. Overall the mean devia-
tion for the target population was 39 % (exact number, positive/negative differences 
included). Mean deviations by year were 42 % (2011), 15 % (2012), 65 % (2013) and 35 
% (2014/2015). Therapeutic areas with the highest deviations concerned “Infectious 
Diseases” (110 %), “Metabolic Diseases” (51 %) and “Oncology” (28 %). These areas 
accounted for 9, 34 and 27 % of the 147 assessments, respectively. Further results on 
e.g. min/max, subgroups, sensitivity analyses excluding deviations ≥ 80 % (signaling 
a difference in definition) will be presented. ConClusions: Epidemiological data 
presented by pharmaceutical companies and G-BA differs considerably. A learning 
curve from 2011 to 2014 is not clearly visible. Susceptible therapeutic areas with high 
deviations are infectious diseases, metabolic diseases and oncology. The poster will 
discuss possible reasons, including data sources.
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objeCtives: Identify within the top 5 EU countries where innovative pharmaceuti-
cal prices decrease the most. Methods: Average price changes over time as well as 
average time to first price cuts were analysed for pharmaceuticals approved by the 
European Medicines Agency (EMA), priced in each market in 2009 and afterwards, 
which are still patent-protected and reimbursed in all analysed markets. Results: 
Overall, the majority of the innovative drugs that are reimbursed and still patent-
protected have not experienced a price change in each of the market studied since 
2009. Over the period analysed, Germany and France are the countries where the 
largest number of innovative drugs experienced a price cut (around 37% of the 
samples analysed for both countries). Price cuts commonly occur after 1.2 year 
on average in Germany and 1.7 year in France. Drugs assessed under the AMNOG 
reform in Germany saw their prices drop by an average of 17%. In Italy, Spain and 
the United Kingdom, the part of innovative pharmaceuticals experiencing price 
cuts is more limited, 10.6%, 12.9% and 16.9%. Additionally, the average price cut is 
small. ConClusions: Within the EU top 5, price cuts for innovative pharmaceuti-
cals are more likely to be implemented in Germany as well as in France. In Germany, 
the AMNOG reform has had a significant impact on prices of drugs that completed 
the process. In France, the majority of the price cuts occurred for drugs that are not 
deemed innovative (ASMR rating of IV or V); which are therefore not granted the 
European level price guarantee for a five-year period. In Italy, Spain and the United 
Kingdom, price cuts do not occur regularly, at least at the list level. Other studies 
have demonstrated that prices tend to be lower at launch but are more likely to 
remain constant over time.
PHP14
outPatient utilization and Quality aPPraisal of antibiotics in 
turkey
Demir C, Gursoy K, Ozturk Y, Koselerli R
Turkish Social Security Institution, Ankara, Turkey
objeCtives: Antibiotic use is of great importance in terms of public health since 
misuse can result in antibiotic resistance. Therefore, evaluating antibiotic consump-
tion is essential. The objective of this study is to analyze the outpatient utiliza-
tion and measure the quality of antibiotic use in Turkey. Methods: Data on the 
total outpatient consumption of antibacterials for systemic use (J01) from 2010 to 
2013 were aggregated from the Turkish Social Security Institution (SGK) at the level 
of active ingredient and then expressed in Defined Daily Doses (DDD) per 1000 
inhabitant per day according to WHO guideline. Annual growth rates of utilization 
were examined. Moreover, 5 of the ESAC Quality Indicators for Consumption of 
Antimicrobials for Systemic Use were computed according to ECDC Survelliance 
Report 2012. Results: While utilization in 2011 boosted by 28% and reached 37 
DDD per 1000 inhabitants per day mostly due to the new drug penetration to the 
market, the figure reduced to 35 in 2013, the highest among EU countries. J01C 
ATC-3 group received the largest share (43,5%) from the total J01 consumption, 
followed by J01D and J01F, all three constituting nearly 88%. As quality indicators, 
relative use of beta lactamase-sensitive penicillins (J01CE_%) and fluoroquinolones 
(J01MA_%) shrank in each year whereas the ratio of broad to narrow spectrum 
antibacterials rose from 11 in 2010 to 17,1 in 2013. Additionally, relative use of com-
binations of penicillins including beta-lactamase inhibitors (J01CR_%) and third 
and fourth-generation cephalosporins (J01DD+DE_%) reached to 37,5% and 13,3% 
respectively in 2013, all indicating misprescribing and hence leading to antibiotic 
resistance. ConClusions: Compared to European countries, antibiotic consump-
tion in Turkey is quite high and there occurs a shift from narrow spectrum antibiot-
ics to broad ones. As a solution, rational drug use and prescription guidelines can 
be policy tools to reduce consumption and improve quality.
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objeCtives: From 2001 onwards, a wave of new innovative medicines has been 
introduced in the Greek pharmaceutical market. Based on this, the purpose of this 
study is to identify and quantify the effects of the increasing penetration of innova-
tive medicines on pharmaceutical spending in Greece during the period 2001-2014, 
Prevalence of antibiotic resistant bacteria has steadily increased over the 7-year 
period alongside that of antibiotic usage. Association between antibiotic resistance 
and clinical factors including antibiotic consumption, site of infection and severity of 
infection will be examined and a mathematical model predicting bacterial resistance, 
which controls for these factors, is being constructed.
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objeCtives: The impact of chronic rhinosinusitis (CRS) on healthcare resources, 
productivity and health-related quality of life (HRQoL) is under-recognized and the 
condition under-treated. The objective of this study was to identify the extent of 
the human and economic impact of CRS. Methods: A comprehensive literature 
search of Medline and EMBASE (2000- January 2015) was performed. Eligibility crite-
ria included patient-reported CRS or a CRS diagnosis, retrospective and prospective 
designs. Abstracts or full text articles were systematically selected if they presented 
data for patients with a diagnosis of CRS, and search terms relevant to CRS, and 
its human and economic burden were applied. Results: The search yielded 786 
titles and ultimately 32 abstracts/articles met the eligibility criteria. People with CRS 
have significantly worse physical, emotional, mental and social HRQoL compared 
to the general population. They are also three times as likely to report their health 
as poor compared to those with another chronic condition, and among those with 
medically refractory CRS, 49% report anxiety/depression, while 31% report problems 
with usual daily activities. In addition, CRS is associated with a significant rise 
in costs due to an increased need for primary/secondary care, emergency room 
visits, and prescription refills. Comparatively, medically refractory CRS resulted 
in a significantly higher indirect cost than diabetes, migraine or severe asthma; 
the cost of lost productivity was estimated to be US$10,077 annually per patient in 
the US, and increased with severity. The longer the time delay between diagnosis 
and sinus surgery (SS), the greater the need for CRS-related visits and prescrip-
tions, rendering delayed SS economically inefficient. However, the cost of managing 
complications of SS (nasal bleeds and cerebrospinal fluid leaks) more than doubles 
the cost of the procedure itself. ConClusions: Results consistently demonstrate 
that CRS imposes a substantial human and economic burden on patients and soci-
ety, especially medically refractory CRS.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all healthcare stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study 
was to analyze trends in the use of health economic information for developing 
clinical guidelines. Methods: A systematic literature search was undertaken for 
the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines 
published between 2003-2015 were included. For guidelines which met the search 
criteria, data was collected for the name of the authors, indication, year of publi-
cation, country/region, and context of use of cost/economic evidence. Results: 
Sixteen clinical guidelines published between 2003-2015 met the inclusion criteria 
for specific mention of cost/economic evidence. More than 50% of these guidelines 
were published between 2006-2015. For indication, 3 out of 16 guidelines were for 
diabetes, while the rest were for different indications. In these16 guidelines “cost 
effectiveness” was mentioned 14 times, either referencing cost-effectiveness data 
or to mention the importance of such data for selecting treatment options. The 
guidelines commonly cite high cost of disease or high economic burden as one of 
the considerations for developing new recommendations (11 out of 16). Another 
term that was commonly used by these guidelines was “cost-benefit,” which was 
mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 out 
of 16 times) in these guidelines. ConClusions: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations. Findings from 
this study might aid drug and device manufacturers in understanding the context of 
use of such information and allow them to tailor their product development plans 
for generating such evidence.
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objeCtives: Dossiers for German benefit assessments on drugs require epidemio-
logical data. The number of statutory health insured patients in the target population 
is needed; basically the claimed number of patients with added benefit. This number 
is presented by pharmaceutical companies, evaluated/adapted during assessment 
and then included in G-BAs final decisions. The aim of this study is to compare the 
epidemiological data presented by companies and G-BA in order to assess deviations 
overall, by year and by therapeutic area. Time trends, susceptible therapeutic areas 
and possible reasons may be delineated. Methods: All relevant documents were 
